Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Rheumatoid arthritis market

Nature Reviews Drug Discovery volume 4, pages 11–12 (2005)Cite this article

In patients who suffer from rheumatoid arthritis (RA), the body, for unknown reasons, directs a hostile autoimmune response against joint cavities, which results in progressive, painful destruction of joint tissues. Worldwide, approximately 1–2% of the population is thought to be affected by RA, and one in three patients is likely to become severely disabled within 20 years. Onset often occurs between the ages of 25 and 50 years and is three times more prevalent in women than men. There are currently three major product classes being used for the treatment of RA that offer significant clinical and quality-of-life improvements for sufferers.

Treatment trends

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 2: Forecast growth rates for the rheumatoid arthritis (RA) market.
Figure 1: Population prevalence.

Author information

Authors and Affiliations

  1. Pharmaceuticals and Biotechnology Consultants at Wood Mackenzie, 5th Floor, Tower 42, Old Broad Street, London, EC2N 1HN, UK

    Claire Mount & James Featherstone

Authors
  1. Claire Mount
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Featherstone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claire Mount.

Related links

Related links

FURTHER INFORMATION

The Arthritis foundation

National Institutes of Health

National Rheumatoid Arthritis Society 

Entrez Gene

COX2

TNFa

OMIM

RA

Non-Hodgkin's lymphoma

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mount, C., Featherstone, J. Rheumatoid arthritis market. Nat Rev Drug Discov 4, 11–12 (2005). https://doi.org/10.1038/nrd1611

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1611

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing